SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Tamoxifen	Clomiphene citrate	Anastrozole
Research Topic	Clinical / Endocrine Pharmacology	Clinical / Endocrine Pharmacology	Clinical / Endocrine Pharmacology
Pharmacology	Selective estrogen receptor modulator medicine	Selective estrogen receptor modulator medicine	Nonsteroidal aromatase inhibitor medicine
PrimeCore Class	Class AApproved in a bounded context	Class AApproved in a bounded context	Class AApproved in a bounded context
Evidence Grade	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence
Evidence boundary	Tamoxifen is classified here as Selective estrogen receptor modulator medicine. Large controlled oncology evidence supports product-specific breast-cancer indications and prevention contexts. FDA-authorised prescription products exist for defined oncology contexts; WADA prohibits SERMs at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	Clomiphene citrate is classified here as Selective estrogen receptor modulator medicine. Prescription labels support bounded ovulatory-dysfunction use; off-label endocrine use is not equivalent to an approved indication. U.S. prescription labels exist for defined female infertility contexts; WADA prohibits clomifene at all times under hormone and metabolic modulators. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	Anastrozole is classified here as Nonsteroidal aromatase inhibitor medicine. Randomised oncology evidence supports defined breast-cancer contexts, not bodybuilding or routine adjunct use. FDA-authorised prescription products exist for defined breast-cancer indications; WADA prohibits aromatase inhibitors at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	Insufficient data in the current dataset
Limitations	Tamoxifen molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	Clomiphene citrate molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	Anastrozole molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use
Sources	DailyMed · Tamoxifen human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	DailyMed · Clomiphene citrate human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	DailyMed · Anastrozole human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.